These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

965 related items for PubMed ID: 11051136

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43. Hydrosoluble medicated nail lacquers: in vitro drug permeation and corresponding antimycotic activity.
    Monti D, Saccomani L, Chetoni P, Burgalassi S, Senesi S, Ghelardi E, Mailland F.
    Br J Dermatol; 2010 Feb 01; 162(2):311-7. PubMed ID: 19886884
    [Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. Efinaconazole 10% solution in the treatment of onychomycosis of the toenails.
    Joseph WS, Vlahovic TC, Pillai R, Olin JT.
    J Am Podiatr Med Assoc; 2014 Feb 01; 104(5):479-85. PubMed ID: 25275736
    [Abstract] [Full Text] [Related]

  • 48. A clinical and laboratory study of ciclopirox olamine (8% Batrafen) in the treatment of onychomycosis.
    Yu B, Zhou G, Wang B, Ben Y, Yan H, Shao Y, Wang B.
    Chin Med Sci J; 1991 Sep 01; 6(3):166-8. PubMed ID: 1838936
    [Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50. Tavaborole 5% Topical Solution for the Treatment of Toenail Onychomycosis in Pediatric Patients: Results from a Phase 4 Open-Label Study.
    Rich P, Spellman M, Purohit V, Zang C, Crook TJ.
    J Drugs Dermatol; 2019 Feb 01; 18(2):190-195. PubMed ID: 30811142
    [Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. Ciclopirox nail lacquer 8%: in vivo penetration into and through nails and in vitro effect on pig skin.
    Ceschin-Roques CG, Hänel H, Pruja-Bougaret SM, Luc J, Vandermander J, Michel G.
    Skin Pharmacol; 1991 Feb 01; 4(2):89-94. PubMed ID: 1831626
    [Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. Topical therapy for toenail onychomycosis: an evidence-based review.
    Gupta AK, Daigle D, Foley KA.
    Am J Clin Dermatol; 2014 Dec 01; 15(6):489-502. PubMed ID: 25257931
    [Abstract] [Full Text] [Related]

  • 55. Efficacy and safety of topical terbinafine 10% solution (MOB-015) in the treatment of mild to moderate distal subungual onychomycosis: A randomized, multicenter, double-blind, vehicle-controlled phase 3 study.
    Gupta AK, Surprenant MS, Kempers SE, Pariser DM, Rensfeldt K, Tavakkol A.
    J Am Acad Dermatol; 2021 Jul 01; 85(1):95-104. PubMed ID: 32585278
    [Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. Tavaborole in Difficult-to-Treat Onychomycosis Cases: A Post-hoc Assessment of Phase III Subjects.
    Aly R, Gupta AK, Winter T, Zane LT, Vlahovic T.
    J Drugs Dermatol; 2017 Oct 01; 16(10):1016-1021. PubMed ID: 29036255
    [Abstract] [Full Text] [Related]

  • 58. Ciclopirox delivery into the human nail plate using novel lipid diffusion enhancers.
    Hafeez F, Hui X, Selner M, Rosenthal B, Maibach H.
    Drug Dev Ind Pharm; 2014 Jun 01; 40(6):838-44. PubMed ID: 23600655
    [Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60. A phase II, randomized, double-blind, placebo-controlled, parallel group, dose-ranging study to investigate the efficacy and safety of 4 dose regimens of oral albaconazole in patients with distal subungual onychomycosis.
    Sigurgeirsson B, van Rossem K, Malahias S, Raterink K.
    J Am Acad Dermatol; 2013 Sep 01; 69(3):416-25. PubMed ID: 23706639
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 49.